|Day Low/High||18.21 / 18.84|
|52 Wk Low/High||8.31 / 24.43|
With the stock of the drugmaker hovering around $23 a share and its reputation bloodied, CEO Joe Papa tried to explain his company's comeback efforts to investors.
Insurgent managers had another busy year. But behind the numbers there were some fascinating trends and surprising tactics. Here's our review of the year that was.
The drugmaker's stock has rallied about $10 in just a few weeks, so a period of consolidation or sideways movement would be expected.
In markets like this, Jim Cramer says, tune out the noise and look at individual stocks like Disney, Boeing and Caterpillar.
Not all stocks are created equal and it's the CEOs who make the difference.
There are plenty of reasons why the stock market isn't falling, from defense and aerospace, to booming energy, to reduced regulation.
Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.
The notes are due in 2025. Proceeds from the offering will help pay down some of Valeant's more than $26 billion debt load.
The stock is performing better than it has in a long time.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMZN, CKH, GDDY, PRSC, QGEN, SHLM, VRX Downgrades: BRG, CZWI, FBP, HAIN, LNCE, PIH, TAIT, TPR, TTWO Initiations: ASIX, CWH Read on to get TheStreet Quant Ratings' detailed report:
Valeant has long been a stock that nobody wanted to touch -- but drama-free earnings and a bullish breakout move are actually making this stock look buyable in the final stretch of 2017.
Here's what you need to know now for Tuesday, Nov. 7.
The insurgent hedge fund manager, who suggested he may be back in 2018 with another boardroom battle, fails in his effort to elect three dissident directors to the board of the payroll processor.
U.S. stock futures suggest Wall Street will open mixed on Tuesday, after the benchmark indexes rallied to fresh records during the previous trading session.
Valeant will divest its subsidiary Sprout Pharmaceuticals to former Sprout shareholders after Sprout accused Valeant of mishandling the launch and marketing of one of its drugs.
Wages and job numbers rose less than expected, but September payrolls were advised to reverse a loss.
Walt Disney, the largest entertainment company in the world, will open its books for investors on Thursday. But until then, all eyes on the surprising arrest of Saudi Prince Alwaleed Bin Talal.
Will the benign backdrop continue next week? Cramer has a defensive game plan, in case earnings chill the market.
Apple carries the Dow Jones Industrial Average and broader markets to records to close out the week.
Apple could carry the Dow Jones Industrial Average to new records but only if the blue-chip index can hold onto small gains through the afternoon session.
Valeant subsidiary Bausch + Lomb, along with Nicox S.A., received FDA application approval for a new glaucoma drug.
Stocks hold mixed on Friday, Nov. 3, as markets digest a strong rebound in jobs growth but weaker wages.
Stock futures hold higher on Friday, Nov. 3, as job growth rebounds in October after hurricanes wreaked havoc with the September number.
First Prostaglandin Analog with one of its Metabolites Being Nitric Oxide Approved to Provide Consistent and Sustained IOP Reduction Through 12 Months
Influential shareholder advisory firm supports all of the activist investor's director candidates in a proxy war set to conclude on Nov. 7.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.